Director at Silexion Therapeutics (SLXN) receives new share and option grants

Rhea-AI Filing Summary

Abramov Dror Yosef reported acquisition or exercise transactions in this Form 4 filing.

Silexion Therapeutics Corp director Abramov Dror Yosef reported equity awards on February 20, 2026. He received 9,091 ordinary shares through a grant of fully vested restricted share units that were immediately settled into shares for his director services, as approved by the board.

He was also granted 10,685 stock options to buy ordinary shares, with these options vesting in full on the one-year anniversary of the board’s approval date and expiring ten years after that approval. Following these awards, he held 10,180 ordinary shares directly, and a separate line shows 935 stock options as an existing holding included for informational purposes.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Abramov Dror Yosef

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy ordinary shares)	10,685	$0.00	--
Grant/Award	Ordinary Shares	9,091	$0.00	--
holding	Stock Option (right to buy ordinary shares)	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 10,685 shares (Direct); Ordinary Shares — 10,180 shares (Direct)

Footnotes (1)

1. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of the Reporting Person's director services to the Issuer. The grant was approved by the Issuer's board of directors. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, which grant was approved by the Issuer's board of directors. The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abramov Dror Yosef

(Last) (First) (Middle)

13 ZAMENHOF STREET

(Street)

HERZLIYA L3 4659213

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Silexion Therapeutics Corp [ SLXN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/20/2026		A(1)		9,091	A	$0	10,180	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	$1.65	02/20/2026		A(2)		10,685		02/12/2027(3)	02/12/2036(3)	Ordinary Shares	10,685	$0	10,685	D
Stock Option (right to buy ordinary shares)(4)	$18.9							02/09/2026	02/09/2035	Ordinary Shares	935		935	D

Explanation of Responses:

1. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of the Reporting Person's director services to the Issuer. The grant was approved by the Issuer's board of directors.

2. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, which grant was approved by the Issuer's board of directors.

3. The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.

4. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

	/s/ Mirit Horenshtein Hadar, Attorney-in-fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Silexion Therapeutics (SLXN) report for Abramov Dror Yosef?

Silexion Therapeutics reported that director Abramov Dror Yosef received grants of ordinary shares and stock options on February 20, 2026. The awards were approved by the board and relate to his director services, increasing his directly held share and option positions in the company.

How many Silexion Therapeutics (SLXN) shares did the director receive in this Form 4?

The director received 9,091 ordinary shares of Silexion Therapeutics through fully vested restricted share units. These RSUs were immediately settled into underlying ordinary shares as compensation for his director services, following approval of the grant by the company’s board of directors.

What stock options were granted to the Silexion Therapeutics (SLXN) director?

The director was granted 10,685 stock options to purchase Silexion Therapeutics ordinary shares. These options vest in full on the one-year anniversary of the board’s approval of the grant and expire on the ten-year anniversary of that same approval date.

What are the director’s Silexion Therapeutics (SLXN) ordinary share holdings after the grant?

After the reported equity grant, the director directly held 10,180 ordinary shares of Silexion Therapeutics. This total reflects the addition of 9,091 ordinary shares received from fully vested restricted share units that were immediately settled into shares approved by the company’s board.

How many Silexion Therapeutics (SLXN) stock options does the director hold after these transactions?

Following the new option grant of 10,685 stock options, a separate informational line in the filing shows 935 stock options as an existing holding. The filing notes that no new transactions occurred for that 935-option position; it is included only to reflect current holdings.